Which companies are Center Laboratories's closest peers?

The cockpit's peer set: Hunan Fangsheng Pharmaceutical (603998.SS), FDC (FDC.NS), Earth (4985.T), Hubei Biocause Heilen Pharmaceutical (301211.SZ), Nuvectis Pharma (NVCT), Mochida Pharmaceutical (4534.T), Immix Biopharma (IMMX), Zhejiang Wecome Pharmaceutical (300878.SZ).

How has Center Laboratories stock performed?

Over six months to 6 Nov 2026 the shares returned -27.9% against -5.6% for the median peer; over one year -16.6%.

← CockpitCompetitor Analysis › 4123.TWO Center Laboratories, Inc.Open in the cockpit ↗

Center Laboratories, Inc.4123.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major

Momentum weak 31

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$676M

US dollars, full cap

Free float

78%

of shares outstanding

$/day

$1.06M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-4.7 pp

WACC 5.0%

Hurdle

+35 pp

Req g minus delivered

Close · TWDNT$28.20

1D-2.4%

1W-1.2%

1M-8.6%

3M-24.7%

6M-27.9%

YTD-32.2%

1Y-16.6%

ATR %2.3%

52w lowhigh45.1% off high

What Center Laboratories does

No business profile yet.

Center Laboratories at a glance

Size Center Laboratories (4123.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $676M, the 350th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$28.20 on 6 Nov 2026.

Performance Over six months the shares fell 27.9%, against -5.6% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue grew 3.6% over the last twelve months (peer median +14.1%); the operating margin is 4.5% (peer median 9.9%).

Valuation It trades at 13.6× enterprise value to sales against a peer median of 2.5× (2nd most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 51% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +35 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.7 points below its cost of capital (5.0% WACC).

Relative performance

Six months, rebased to 100: Center Laboratories against the median of its 20 peers (local-currency closes).

Center Laboratories financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	NT$1.66B	NT$1.52B	NT$1.62B	NT$1.39B	NT$768M
Revenue growth	—	-6%	+16%	+82%	—
Gross profit	NT$645M	NT$552M	NT$678M	NT$618M	NT$393M
EBITDA	NT$253M	NT$257M	NT$391M	NT$221M	NT$99.6M
Net income	NT$1.02B	NT$9.32B	-NT$1.10B	-NT$995M	NT$102M
Free cash flow	NT$254M	-NT$21.1M	NT$317M	-NT$774M	NT$226M
Capital expenditure	NT$158M	NT$208M	NT$178M	NT$172M	NT$8.43M
Total debt	NT$4.10B	NT$4.70B	NT$6.53B	NT$5.62B	NT$3.47B

Quarterly statements and history in the cockpit →

Center Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Center Laboratories is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Center Laboratories is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Center Laboratories is the large dot.

Center Laboratories competitors and peer comparison

How Center Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Center Laboratories against its 20 peers (data as of 6 Nov 2026)
Measure	4123.TWO	Peer median	Rank in peer set
1-month return	-8.6%	-4.9%	10th lowest of 21
6-month return	-27.9%	-5.6%	3rd lowest of 21
Distance from 52-week high	-45.1%	-29.1%	5th lowest of 21
Revenue growth (TTM)	+3.6%	+14.1%	5th lowest of 17
Operating margin	4.5%	9.9%	6th lowest of 17
EV / Sales	13.6×	2.5×	2nd most expensive of 17
Growth the price implies (Req g, 7 yrs)	50.8%	1.1%	most demanding of 10
Growth delivered (Del g)	+16.2%	+7.9%	3rd highest of 10
Hurdle (Req g minus delivered)	+34.7 pp	+2.5 pp	most demanding of 10
ROIC minus cost of capital	-4.7 pp	-1.8 pp	6th lowest of 15
EV / EBITDA	89.4×	8.2×	most expensive of 8
Net debt / EBITDA	1.0×	-1.2×	2nd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Center Laboratories 4123.TWO	Taiwan	$676M	-28%	+4%	5%	13.6×	50.8%	+16.2%
Hunan Fangsheng Pharmaceutical 603998.SS	China	$678M	-6%	+10%	19%	2.5×	-2.4%	+6.4%
FDC FDC.NS	India	$672M	+4%	+10%	14%	2.5×	25.9%	+10.3%
Earth 4985.T	Japan	$682M	+6%	+6%	4%	0.6×	-2.5%	-1.8%
Hubei Biocause Heilen Pharmaceutical 301211.SZ	China	$682M	-5%	+13%	4%	6.2×	n/a	n/a
Nuvectis Pharma NVCT	United States	$683M	+79%	n/a	n/a	n/a	n/a	n/a
Mochida Pharmaceutical 4534.T	Japan	$683M	-6%	+15%	9%	0.7×	n/a	n/a
Immix Biopharma IMMX	United States	$668M	-17%	n/a	n/a	n/a	n/a	n/a
Zhejiang Wecome Pharmaceutical 300878.SZ	China	$666M	+10%	+40%	-65%	19.0×	n/a	n/a
Jenkem Technology 688356.SS	China	$686M	-23%	+52%	11%	10.9×	41.4%	+11.2%
Shandong Wit Dyne Health 000915.SZ	China	$687M	-33%	-36%	36%	2.5×	n/a	n/a
Sun Pharma Advanced Research SPARC.NS	India	$665M	+16%	+3,141%	84%	2.6×	n/a	n/a
Luoxin Pharmaceuticals Group Stock 002793.SZ	China	$664M	-26%	-10%	-9%	2.2×	0.3%	-17.9%
Lepu Biopharma 2157.HK	Hong Kong	$663M	-45%	+47%	7%	5.1×	n/a	n/a
Zevra Therapeutics ZVRA	United States	$690M	+4%	+75%	31%	3.4×	0.0%	+51.6%
Shandong Jincheng Pharmaceutical 300233.SZ	China	$661M	-25%	+2%	4%	1.4×	1.1%	-1.6%
Achieve Life Sciences ACHV	United States	$692M	+29%	n/a	n/a	n/a	n/a	n/a
Beijing Beilu Pharmaceutical 300016.SZ	China	$692M	-16%	+23%	11%	3.2×	10.3%	+7.9%
Sagimet Biosciences SGMT	United States	$693M	+28%	n/a	n/a	n/a	n/a	n/a
Philogen PHIL.MI	Italy	$694M	-7%	+295%	79%	0.9×	n/a	n/a
GuiZhou SanLi Pharmaceutical 603439.SS	China	$657M	-4%	-6%	5%	2.9×	23.2%	+21.9%

Questions

Which companies are Center Laboratories's closest peers?: The cockpit's peer set: Hunan Fangsheng Pharmaceutical (603998.SS), FDC (FDC.NS), Earth (4985.T), Hubei Biocause Heilen Pharmaceutical (301211.SZ), Nuvectis Pharma (NVCT), Mochida Pharmaceutical (4534.T), Immix Biopharma (IMMX), Zhejiang Wecome Pharmaceutical (300878.SZ).
Is Center Laboratories expensive compared with its peers?: On ev / sales it trades at 13.6× against a peer median of 2.5×, 2nd most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 51% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +35 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Center Laboratories stock performed?: Over six months to 6 Nov 2026 the shares returned -27.9% against -5.6% for the median peer; over one year -16.6%.